Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nutriband Inc (NTRB)

Nutriband Inc (NTRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nutriband (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21 Investor Brand Network - Mon Nov 24, 11:30AM CST

Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern...

NTRB : 4.82 (-4.74%)
Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference Newsfile - Mon Nov 24, 6:16AM CST

Orlando, Florida--(Newsfile Corp. - November 24, 2025) - Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that its Chairman and Co-Founder, Serguei Melnik will present at NobleCon21 - Noble...

NTRB : 4.82 (-4.74%)
Nutriband (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission Investor Brand Network - Tue Oct 28, 10:56AM CDT

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received final meeting minutes from its Sept. 18, 2025, virtual meeting with the U.S. Food...

NTRB : 4.82 (-4.74%)
BMWYY : 29.2000 (+4.58%)
REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch GlobeNewswire - Tue Oct 28, 10:05AM CDT

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...

NTRB : 4.82 (-4.74%)
NTRBW : 1.3300 (unch)
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch GlobeNewswire - Tue Oct 28, 6:00AM CDT

Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received...

NTRB : 4.82 (-4.74%)
NTRBW : 1.3300 (unch)
Nutriband (NASDAQ: NTRB) Founder Gareth Sheridan Returns as CEO to Lead Final Development Phase of AVERSA Fentanyl Investor Brand Network - Mon Oct 27, 11:13AM CDT

Nutriband (NASDAQ: NTRB) today announced that company founder Gareth Sheridan has resumed his role as CEO, effective immediately, following a temporary period during which Co-Founder and Chairman Serguei...

NTRB : 4.82 (-4.74%)
Nutriband Co-Founder Gareth Sheridan Returns as CEO GlobeNewswire - Mon Oct 27, 6:00AM CDT

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO.   During the period of...

NTRB : 4.82 (-4.74%)
NTRBW : 1.3300 (unch)
Nutriband (NASDAQ: NTRB) Featured in Channelchek Report Highlighting AVERSA Fentanyl Progress Investor Brand Network - Fri Oct 24, 10:57AM CDT

Nutriband (NASDAQ: NTRB), a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s...

NTRB : 4.82 (-4.74%)
Nutriband (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL Investor Brand Network - Fri Oct 10, 10:24AM CDT

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader...

NTRB : 4.82 (-4.74%)
BMWYY : 29.2000 (+4.58%)
Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch GlobeNewswire - Fri Oct 10, 6:00AM CDT

Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in...

NTRB : 4.82 (-4.74%)
NTRBW : 1.3300 (unch)

Barchart Exclusives

Rate Decision, Tech Earnings and Other Key Things to Watch this Week Barchart - Sun Dec 7, 12:00PM CST
Markets face the year's final major policy week as the Federal Reserve's December meeting Wednesday afternoon will determine whether the central bank delivers another rate cut or pauses its easing cycle amid mixed economic signals and persistent inflation concerns. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot